Trial Watch—Oncolytic viruses and cancer therapy

Jonathan Pol, Aitziber Buqué, Fernando Aranda, Norma Bloy, Isabelle Cremer, Alexander Eggermont, Philippe Erbs, Jitka Fucikova, Jérôme Galon, Jean Marc Limacher, Xavier Preville, Catherine Sautès-Fridman, Radek Spisek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

93 Citaten (Scopus)


Oncolytic virotherapy relies on the administration of non-pathogenic viral strains that selectively infect and kill malignant cells while favoring the elicitation of a therapeutically relevant tumor-targeting immune response. During the past few years, great efforts have been dedicated to the development of oncolytic viruses with improved specificity and potency. Such an intense wave of investigation has culminated this year in the regulatory approval by the US Food and Drug Administration (FDA) of a genetically engineered oncolytic viral strain for use in melanoma patients. Here, we summarize recent preclinical and clinical advances in oncolytic virotherapy.

Originele taal-2Engels
Nummer van het tijdschrift2
StatusGepubliceerd - 1 feb. 2016
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Trial Watch—Oncolytic viruses and cancer therapy'. Samen vormen ze een unieke vingerafdruk.

Citeer dit